Chemical M&A in the First Quarter 2025 and Beyond
Young & Partners shares proprietary analysis and outlook of Chemical M&A in the first quarter of 2025 and the outlook for the M&A market in the rest of 2025.
Biotech and Pharma M&A in the First Quarter 2025 and Beyond
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have affected the Biotech and Pharma M&A market in the first quarter of 2025 and the outlook.
Chemical Executives Deal with Tariffs (ICIS Chemical Business May 9 – May 15, 2025)
ICIS Chemical Business reports on panel discussion (Apollo, Dow and Westlake executives) moderated by Peter Young on April 30, 2025.
Chemical Debt Financing Perks Up (ICIS Chemical Business February 21 – February 27, 2025)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have rebounded chemical debt financings and the outlook for 2025.
Biopharma Business Check – Financing and Review (Pharmaceutical Executive, February 2025)
Young & Partners shares proprietary analysis of the stock market and funding environment in Biotech and Pharma and the outlook for 2025.
Global M&A Treads Water
Young & Partners shares proprietary analysis of the Chemicals M&A market and their outlook for 2025.
Divestitures in the Current Environment
Young & Partners shares proprietary analysis of the Chemicals M&A market and proposes questions for Chemicals owners to think over as significant asset rationalization occurs globally.
Reflections on 2024 and Outlook – Stock Market and Funding
Young & Partners shares proprietary analysis of the stock market and funding environment in Biotech and Pharma and the outlook for 2025.
Reflections on 2024 and Outlook – Senior Management Approach to M&A
Young & Partners shares proprietary analysis and outlook of how managers and executive should approach Biotech and Pharma M&A market in 2025.
Reflections on 2024 and Outlook – Biotech and Pharma M&A
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have affected the Biotech and Pharma M&A market in 2024 and the outlook for 2025.